{
  "docId": "019de076-4b6e-745e-b621-2097373bdc12",
  "docSlug": "454a033dcd11e0912fc4b281c3c86d65",
  "documentTitle": "Innoviva | Results Presentation Deck | 7 slides",
  "authorId": "innoviva",
  "authorName": "Innoviva",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 7,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "appendix_methodology",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 14,
  "notes": "Flowchart shows patient progression from screening to dosing and categorization by infection site.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4b6e-745e-b621-2097373bdc12/4",
  "deckHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12",
  "deckJsonHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12.json",
  "deckAnchorHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.398,
        "x": 0.551,
        "y": 0.208
      },
      "kind": "diagram",
      "text": "Enrollment and dosing flow chart",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3cb37ff8-017c-485e-9553-d90de4958390",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.398,
        "x": 0.551,
        "y": 0.535
      },
      "kind": "diagram",
      "text": "Sites of infection breakdown",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa5609c5-1862-4e03-9fab-f696576161f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.087,
        "w": 0.385,
        "x": 0.093,
        "y": 0.725
      },
      "kind": "paragraph",
      "text": "Overall, the trial participants were 87% male, 13% female, 55% Black or Black African, and 20% were positive for human immunodeficiency virus (HIV).",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3cad6ea7-3dbb-47cf-a602-55fa27a1190f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.131,
        "w": 0.385,
        "x": 0.093,
        "y": 0.439
      },
      "kind": "paragraph",
      "text": "The majority of participants (744) presented with urogenital infections, followed by rectal infections (114) and pharyngeal infections (81). Participants could be in more than one group.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55fbd510-5690-4327-a823-5b0b9276099a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.065,
        "w": 0.385,
        "x": 0.093,
        "y": 0.261
      },
      "kind": "paragraph",
      "text": "1011 patients were initially screened, with 927 randomized and dosed.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a07ef037-7a9c-4cb7-b792-9bc3094d75a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.019,
        "w": 0.264,
        "x": 0.046,
        "y": 0.938
      },
      "kind": "source-note",
      "text": "Abbreviations: CRO-AZI – ceftriaxone and azithromycin",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e48e9474-d9ea-4fc5-a137-385a1167b4f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.054,
        "w": 0.281,
        "x": 0.046,
        "y": 0.065
      },
      "kind": "title",
      "text": "Study enrollment",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "89a65445-153c-4a20-9354-c62f3078b02c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "690e5dcb-225a-4a99-b9a4-66e60174cc40",
      "evidence": "The majority of participants (744) presented with urogenital infections, followed by rectal infections (114) and pharyngeal infections (81).",
      "confidence": 0.7
    },
    {
      "name": "Data-Ink Ratio",
      "slug": "data-ink-ratio",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "064dc899-c871-46e0-b081-d351fbd54021",
      "evidence": "diagram/process: Enrollment and dosing flow chart, diagram/process: Sites of infection breakdown",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 7,
      "from": 2,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "cc60ccb3-7bfb-482b-bd2f-71df33588aa9",
      "evidence": "Implication of antibiotic resistance and need for new treatments",
      "position": 0,
      "objective": "What are the consequences of not adopting Zoliflodacin?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}